ImmunityBio (IBRX) Competitors $5.28 +0.07 (+1.34%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IBRX vs. TGTX, IOVA, KRYS, VCYT, HRMY, GMAB, VTRS, SMMT, RDY, and SRPTShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include TG Therapeutics (TGTX), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Veracyte (VCYT), Harmony Biosciences (HRMY), Genmab A/S (GMAB), Viatris (VTRS), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "medical" sector. ImmunityBio vs. TG Therapeutics Iovance Biotherapeutics Krystal Biotech Veracyte Harmony Biosciences Genmab A/S Viatris Summit Therapeutics Dr. Reddy's Laboratories Sarepta Therapeutics TG Therapeutics (NASDAQ:TGTX) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation. Do insiders & institutionals believe in TGTX or IBRX? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 10.5% of TG Therapeutics shares are owned by company insiders. Comparatively, 83.4% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer TGTX or IBRX? In the previous week, TG Therapeutics had 10 more articles in the media than ImmunityBio. MarketBeat recorded 15 mentions for TG Therapeutics and 5 mentions for ImmunityBio. TG Therapeutics' average media sentiment score of 0.53 beat ImmunityBio's score of 0.06 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, TGTX or IBRX? TG Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$346.72M12.01$12.67M$0.6144.10ImmunityBio$620K5,931.74-$583.20M-$0.97-5.44 Does the MarketBeat Community believe in TGTX or IBRX? TG Therapeutics received 651 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 76.79% of users gave TG Therapeutics an outperform vote while only 16.00% of users gave ImmunityBio an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65576.79% Underperform Votes19823.21% ImmunityBioOutperform Votes416.00%Underperform Votes2184.00% Is TGTX or IBRX more profitable? TG Therapeutics has a net margin of 27.60% compared to ImmunityBio's net margin of -45,691.66%. TG Therapeutics' return on equity of 57.73% beat ImmunityBio's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics27.60% 57.73% 26.67% ImmunityBio -45,691.66%N/A -108.04% Which has more risk and volatility, TGTX or IBRX? TG Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do analysts recommend TGTX or IBRX? TG Therapeutics currently has a consensus price target of $36.33, indicating a potential upside of 35.07%. ImmunityBio has a consensus price target of $4.75, indicating a potential downside of 10.04%. Given TG Therapeutics' higher possible upside, research analysts plainly believe TG Therapeutics is more favorable than ImmunityBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ImmunityBio 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryTG Therapeutics beats ImmunityBio on 15 of the 19 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.68B$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-5.4412.18115.5615.18Price / Sales5,931.74332.351,484.3492.77Price / CashN/A148.6339.6634.07Price / Book-6.004.024.665.02Net Income-$583.20M-$42.25M$119.06M$225.46M7 Day Performance-0.75%8.06%0.80%0.37%1 Month Performance47.90%8.71%5.65%3.57%1 Year Performance42.70%32.10%36.76%29.44% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio0.8202 of 5 stars$5.28+1.3%$4.75-10.0%+62.5%$3.68B$620,000.00-5.44590TGTXTG Therapeutics4.7929 of 5 stars$25.13-2.3%$34.43+37.0%+165.8%$3.88B$346.72M41.20290Upcoming EarningsAnalyst ForecastNews CoverageIOVAIovance Biotherapeutics3.7643 of 5 stars$11.04+2.1%$22.33+102.3%+189.1%$3.09B$32.77M-6.61500Upcoming EarningsKRYSKrystal Biotech4.639 of 5 stars$175.53-0.4%$196.75+12.1%+47.8%$5.01B$166.23M48.09229Upcoming EarningsVCYTVeracyte4.1724 of 5 stars$35.00+1.8%$35.67+1.9%+62.9%$2.68B$399.58M-46.67790Upcoming EarningsHRMYHarmony Biosciences4.9032 of 5 stars$33.80-18.5%$44.38+31.3%+34.9%$1.92B$656.11M17.33200Earnings ReportAnalyst ForecastInsider SellingShort Interest ↓Analyst RevisionNews CoverageHigh Trading VolumeGMABGenmab A/S4.644 of 5 stars$22.57-2.4%$45.20+100.3%-22.1%$14.94B$19.02B18.652,204Upcoming EarningsVTRSViatris2.5641 of 5 stars$11.89+1.3%$14.00+17.7%+30.3%$14.19B$15.24B-21.6238,000Upcoming EarningsSMMTSummit Therapeutics2.8889 of 5 stars$18.65-14.6%$36.00+93.0%+873.8%$13.51B$700,000.00-81.08105Analyst ForecastNews CoverageRDYDr. Reddy's Laboratories1.3043 of 5 stars$74.16-1.3%$87.00+17.3%+13.4%$12.38B$288.51B18.5427,048Gap DownSRPTSarepta Therapeutics4.9545 of 5 stars$127.78-1.9%$182.95+43.2%+61.1%$12.08B$1.50B283.961,314Upcoming Earnings Related Companies and Tools Related Companies TGTX Alternatives IOVA Alternatives KRYS Alternatives VCYT Alternatives HRMY Alternatives GMAB Alternatives VTRS Alternatives SMMT Alternatives RDY Alternatives SRPT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IBRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
